

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeOne Medicines Ltd.

百濟神州有限公司

(a corporation incorporated under the laws of Switzerland)

(Stock Code: 06160)

DATE OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ANNOUNCEMENT AND NOTICE OF BOARD ACTION

BeOne Medicines Ltd. (the “**Company**”) hereby announces that it will report its fourth quarter and full year 2025 financial results prepared in accordance with U.S. Generally Accepted Accounting Principles (“**U.S. GAAP**”) and the applicable rules of the U.S. Securities and Exchange Commission (the “**SEC**”) on Thursday, February 26, 2026 (after the trading hours of the Hong Kong Stock Exchange). The fourth quarter and full year 2025 financial results will be reviewed and approved by the board of directors (the “**Board**”) of the Company on February 26, 2026 (Hong Kong Time).

Following the release of the financials, the Company will host a conference call with the Company’s management at 8:00 a.m. U.S. Eastern Time on Thursday, February 26, 2026 (9:00 p.m. Hong Kong Time on Thursday, February 26, 2026).

The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company’s website at <https://ir.beonemedicines.com>. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website.

The Company will further issue an announcement of its audited financial results for the year ended December 31, 2025 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**HK Listing Rules**”) on or before March 31, 2026, which are expected to be the same as the annual results prepared in accordance with U.S. GAAP and the applicable rules of the SEC, except for specific additional information required by the HK Listing Rules, together with a reconciliation of the Company’s annual results from U.S. GAAP to International Financial Reporting Standards.

By order of the Board
BeOne Medicines Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, February 11, 2026

As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang as Non-executive Director, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp and Mr. Qingqing Yi as Independent Non-executive Directors.